A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1 High Metastatic Non-Small Cell Lung Cancer
Efficacy and Safety of Remibrutinib after Switching from Ocrelizumab in Participants Living with Relapsing Multiple Sclerosis, Followed by Open-Label Treatment with Remibrutinib
